Revvity, Inc. (NYSE:RVTY) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Revvity, Inc. (NYSE:RVTY) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $118.91.

A number of analysts recently commented on the company. Barclays upped their price objective on Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $88.00 to $125.00 in a report on Thursday, January 4th. Stifel Nicolaus upped their target price on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a report on Friday, February 2nd. KeyCorp boosted their price objective on shares of Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Finally, UBS Group cut Revvity from a “buy” rating to a “neutral” rating and raised their target price for the stock from $105.00 to $125.00 in a report on Tuesday, January 16th.

Insider Transactions at Revvity

In other news, insider Prahlad R. Singh sold 21,217 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the sale, the insider now owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Revvity

Institutional investors and hedge funds have recently made changes to their positions in the business. Parkside Financial Bank & Trust purchased a new stake in shares of Revvity in the fourth quarter valued at approximately $25,000. Gladius Capital Management LP lifted its holdings in shares of Revvity by 84.1% in the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after buying an additional 106 shares during the period. CENTRAL TRUST Co bought a new position in shares of Revvity during the 4th quarter worth $27,000. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Revvity during the fourth quarter valued at $27,000. Finally, ORG Partners LLC bought a new stake in shares of Revvity in the fourth quarter valued at about $32,000. 86.65% of the stock is currently owned by institutional investors.

Revvity Stock Performance

Shares of Revvity stock opened at $100.86 on Monday. The stock has a market cap of $12.46 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 2.62 and a beta of 1.09. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77. Revvity has a 1 year low of $79.50 and a 1 year high of $135.67. The firm’s 50-day moving average is $104.78 and its 200 day moving average is $101.64.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.15 by $0.10. Revvity had a return on equity of 7.41% and a net margin of 25.20%. The business had revenue of $695.90 million for the quarter. Sell-side analysts anticipate that Revvity will post 4.65 EPS for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, April 18th. This represents a $0.28 annualized dividend and a yield of 0.28%. Revvity’s payout ratio is currently 5.09%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.